Showing 3511-3520 of 5773 results for "".
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- Zeiss Acquires All Shares of Tooz, Maker of Augmented Reality Opticshttps://modernod.com/news/zeiss-acquires-tooz-maker-of-augmented-reality-and-virtual-reality-glasses/2481447/Zeiss announced it has acquired the shares of the joint venture tooz technologies, which was founded together with Deutsche Telekom in 2018 and is developer of high-tech optics in the area of augmented reality. Until now, Zeiss and Deutsche Telekom held 50% of the shares in the sta
- Grifols Enters Into Global Collaboration and Licensing Agreement with Selagine to Develop Immunoglobulin Eye Drops to Treat Dry Eye Diseasehttps://modernod.com/news/grifols-enters-into-global-collaboration-and-licensing-agreement-with-selagine-to-develop-immunoglobulin-eye-drops-to-treat-dry-eye-disease/2481446/Spanish pharma company Grifols announced a global collaboration and licensing agreement with Selagine to treat dry eye disease (DED) with immunoglobulin eye drops. Financial terms of the deal were not disclosed. The potential immunoglobulin treatment would be G
- Akorn Files for Chapter 7 Bankruptcy; to Close All US Siteshttps://modernod.com/news/akorn-pharma-to-close-all-us-sites/2481445/Akorn Pharmaceuticals, a maker of generic and branded drugs, announced it is ceasing operations. The company, which offered more than 20 ophthalmic products, has filed for chapter 7 bankruptcy and is shutting down US operations. The news was first
- FDA Accepts for Priority Review NDA for Primary Vitreoretinal Lymphoma Treatment Candidatehttps://modernod.com/news/fda-accepts-for-priority-review-adx-2191-new-drug-application-for-the-treatment-of-primary-vitreoretinal-lymphoma/2481442/Aldeyra Therapeutics announced that the FDA accepted for Priority Review the new drug application (NDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma. The FDA assigned a Prescription Drug User Fee A
- Iridex Introduces New Research and Showcases Five Events at the AGS Meetinghttps://modernod.com/news/iridex-introduces-new-research-and-showcases-five-events-at-the-ags-meeting/2481441/Iridex announced Part 2 of the evidence-based guidelines series for MicroPulse Transscleral Laser Therapy (TLT) has been published in Clinical Ophthalmology by the international consensus panel of ten glaucoma experts[1].The publication will be available at booth #5 at the 2023 meet
- Post-Hoc Analysis Shows Up to a 59% Reduction in Rate of Vision Loss in Iveric Bio's GA Treatmenthttps://modernod.com/news/iveric-bio-announces-up-to-a-59-reduction-in-rate-of-vision-loss-in-geographic-atrophy-treatment-trials/2481439/Iveric bio announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic at
- New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels From Childhood Vaccineshttps://modernod.com/news/new-data-suggest-uplinza-for-the-treatment-of-nmosd-did-not-increase-the-risk-of-covid-19-or-reduce-antibody-levels-from-childhood-vaccines/2481438/Horizon Therapeutics announced new data suggest Uplinza does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies. Uplinza is the first and only B-cell-depleting monotherapy approved by the FDA and the European Commission for the tre
- Ace Vision Group Appoints Cristos Ifantides, MD, as Director, Clinical Applications Developmenthttps://modernod.com/news/ace-vision-group-appoints-cristos-ifantides-md-as-director-clinical-applications-development/2481436/Ace Vision Group (AVG) announced the appointment of Cristos Ifantides, MD, MBA, as Director, Clinical Applications Development, effective immediately. In his new role, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology
- EyePoint and Rallybio Partner to Evaluate Inhibitor of Complement Component 5 and Durasert Technology for Intraocular Delivery in GAhttps://modernod.com/news/eyepoint-and-rallybio-partner-to-evaluate-inhibitor-of-complement-component-5-and-durasert-technology-for-intraocular-delivery-in-ga/2481435/EyePoint Pharmaceuticals and Rallybio announced a research collaboration aimed at evaluating sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus